Japan dyslipidemia cases to reach 15.3 million by 2035

Japan and France's lower prevalence rates were linked to fewer risk factors such as obesity.

Japan is projected to have approximately 15.3 million diagnosed prevalent cases of dyslipidemia in 2035, according to GlobalData.

The number of diagnosed cases across the seven major markets (7MM) is forecast to increase at an annual growth rate (AGR) of 0.58%, from 131.6 million in 2025 to 139.2 million in 2035.

Dyslipidemia is a medical condition characterised by abnormal levels of lipids in the bloodstream, including cholesterol, low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein cholesterol (HDL-C).

In its latest report, Dyslipidemia: Epidemiology Forecast to 2035, GlobalData estimated that the US would have over 61.4 million diagnosed cases in 2035, the highest number amongst individual countries in the 7MM.

Meanwhile, the 5EU—France, Germany, Italy, Spain, and the UK—are forecast to record a combined 62.6 million cases in 2035.

GlobalData epidemiologists attributed Japan and France's comparatively low total and diagnosed prevalence rates of dyslipidemia to a lower prevalence of risk factors, including overweight and obesity.

“Additionally, studies indicate that Japan has healthier lipid profiles compared with the US and EU markets, as well as a lower prevalence and later onset of cardiovascular disease (CVD),” said Alia Rafiq, Senior Epidemiologist at GlobalData.

Rafiq added that genetic factors may also play a role, noting that dysfunctional mutations of cholesteryl ester transfer protein, which are associated with higher HDL-C levels, have been observed more frequently in the Japanese population than in non-Japanese populations.

In contrast, the UK had the highest AGR of diagnosed dyslipidemia cases and the highest diagnosed prevalence rate of the condition amongst the 7MM in 2025.

The country also had the second-highest diagnosed prevalence of obesity in the 7MM that year, the firm noted.

Rafiq cited risk factors including adherence to a Western diet, limited exercise, and high obesity prevalence as contributing factors to the UK's dyslipidemia burden.

“Further evidence supporting the UK’s high dyslipidemia burden is its high burden of CVD, with CVD being the leading cause of premature death in the UK, according to NHS data. This is significant, as dyslipidemia is a major risk factor of CVD,” she added.